Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL

Patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who received pirtobrutinib (Jaypirca; Eli Lilly) monotherapy showed an 80% reduction in progression-free survival (PFS) compared with patients…